NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 May 28

PMID 35628668

Authors

Shafiq Murad

Susanne Michen

Alexander Becker

Monika Fussel

Gabriele Schackert

Torsten Tonn

Frank Momburg

Achim Temme

Affiliations

Soon will be listed here.

Abstract

In glioblastoma, non-classical human leucocyte antigen E (HLA-E) and HLA-G are frequently overexpressed. HLA-E loaded with peptides derived from HLA class I and from HLA-G contributes to inhibition of natural killer (NK) cells with expression of the inhibitory receptor CD94/NKG2A. We investigated whether NK cells expressing the activating CD94/NKG2C receptor counterpart were able to exert anti-glioma effects. NKG2C+ subsets were preferentially expanded by a feeder cell line engineered to express an artificial disulfide-stabilized trimeric HLA-E ligand (HLA-E*spG). NK cells expanded by a feeder cell line, which facilitates outgrowth of conventional NKG2A+, and fresh NK cells, were included for comparison. Expansion via the HLA-E*spG feeder cells selectively increased the fraction of NKG2C+ NK cells, which displayed a higher frequency of KIR2DL2/L3/S2 and CD16 when compared to expanded NKG2A+ NK cells. NKG2C+ NK cells exhibited increased cytotoxicity against K562 and KIR:HLA-matched and -mismatched primary glioblastoma multiforme (GBM) cells when compared to NKG2A+ NK cells and corresponding fresh NK cells. Cytotoxic responses of NKG2C+ NK cells were even more pronounced when utilizing target cells engineered with HLA-E*spG. These findings support the notion that NKG2C+ NK cells have potential therapeutic value for treating gliomas.

Citing Articles

Potential molecular mechanisms of ETV6-RUNX1-positive B progenitor cell cluster in acute lymphoblastic leukemia revealed by single-cell RNA sequencing.

Qu N, Wan Y, Sui X, Sui T, Yang Y PeerJ. 2024; 12:e18445.

PMID: 39498293 PMC: 11533907. DOI: 10.7717/peerj.18445.

Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy.

Douka S, Papamoschou V, Raimo M, Mastrobattista E, Caiazzo M Pharmaceutics. 2024; 16(9).

PMID: 39339180 PMC: 11434712. DOI: 10.3390/pharmaceutics16091143.

Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma.

Dong S, Zhao M, Zhu J, Li T, Yan M, Xing K Front Immunol. 2024; 15:1442673.

PMID: 39234249 PMC: 11371580. DOI: 10.3389/fimmu.2024.1442673.

NKG2C/ tumor cell expression enhances immunotherapeutic efficacy against glioblastoma.

de Dios O, Ramirez-Gonzalez M, Gomez-Soria I, Segura-Collar B, Manosalva J, Megias D J Immunother Cancer. 2024; 12(8).

PMID: 39214651 PMC: 11367385. DOI: 10.1136/jitc-2024-009210.

ZBTB46 coordinates angiogenesis and immunity to control tumor outcome.

Kabir A, Zeng C, Subramanian M, Wu J, Kim M, Krchma K Nat Immunol. 2024; 25(9):1546-1554.

PMID: 39134750 DOI: 10.1038/s41590-024-01936-4.

References

Brown C, Alizadeh D, Starr R, Weng L, Wagner J, Naranjo A . Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016; 375(26):2561-9. PMC: 5390684. DOI: 10.1056/NEJMoa1610497. View

Friese M, Platten M, Lutz S, Naumann U, Aulwurm S, Bischof F . MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 2003; 63(24):8996-9006. View

Abi-Rached L, Parham P . Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J Exp Med. 2005; 201(8):1319-32. PMC: 2213150. DOI: 10.1084/jem.20042558. View

Lanier L, Corliss B, Wu J, Phillips J . Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity. 1998; 8(6):693-701. DOI: 10.1016/s1074-7613(00)80574-9. View

Michen S, Frosch J, Fussel M, Schackert G, Momburg F, Temme A . Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self. Cytotherapy. 2020; 22(7):354-368. DOI: 10.1016/j.jcyt.2020.02.004. View

Hu P, Hultin L, Hultin P, Hausner M, Hirji K, Jewett A . Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10(3):331-40. View

Michen S, Temme A . Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy. Crit Rev Immunol. 2017; 36(4):329-347. DOI: 10.1615/CritRevImmunol.2017019376. View

Vales-Gomez M, Reyburn H, Erskine R, Lopez-Botet M, Strominger J . Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999; 18(15):4250-60. PMC: 1171501. DOI: 10.1093/emboj/18.15.4250. View

Lauterbach N, Wieten L, Popeijus H, Voorter C, Tilanus M . HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire. Hum Immunol. 2015; 76(8):578-86. DOI: 10.1016/j.humimm.2015.09.003. View

10.

Alexandrov L, Nik-Zainal S, Wedge D, Aparicio S, Behjati S, Biankin A . Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-21. PMC: 3776390. DOI: 10.1038/nature12477. View

11.

Stewart C, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A . Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005; 102(37):13224-9. PMC: 1201584. DOI: 10.1073/pnas.0503594102. View

12.

Shifrin N, Raulet D, Ardolino M . NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol. 2014; 26(2):138-44. PMC: 3984600. DOI: 10.1016/j.smim.2014.02.007. View

13.

Oei V, Siernicka M, Graczyk-Jarzynka A, Hoel H, Yang W, Palacios D . Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. Cancer Immunol Res. 2018; 6(4):467-480. DOI: 10.1158/2326-6066.CIR-17-0207. View

14.

Topfer K, Kempe S, Muller N, Schmitz M, Bachmann M, Cartellieri M . Tumor evasion from T cell surveillance. J Biomed Biotechnol. 2011; 2011:918471. PMC: 3228689. DOI: 10.1155/2011/918471. View

15.

Muller-Durovic B, Grahlert J, Devine O, Akbar A, Hess C . CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age. Aging (Albany NY). 2019; 11(2):724-740. PMC: 6366961. DOI: 10.18632/aging.101774. View

16.

Wolpert F, Roth P, Lamszus K, Tabatabai G, Weller M, Eisele G . HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. J Neuroimmunol. 2012; 250(1-2):27-34. DOI: 10.1016/j.jneuroim.2012.05.010. View

17.

Abel A, Yang C, Thakar M, Malarkannan S . Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9:1869. PMC: 6099181. DOI: 10.3389/fimmu.2018.01869. View

18.

Reardon D, Brandes A, Omuro A, Mulholland P, Lim M, Wick A . Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(7):1003-1010. PMC: 7243167. DOI: 10.1001/jamaoncol.2020.1024. View

19.

Lanier L, Corliss B, Wu J, Leong C, Phillips J . Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 1998; 391(6668):703-7. DOI: 10.1038/35642. View

20.

Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T . Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2017; 20(5):674-686. PMC: 5892140. DOI: 10.1093/neuonc/nox208. View